HomeCompareAUOTY vs JNJ

AUOTY vs JNJ: Dividend Comparison 2026

AUOTY yields 1.87% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 JNJ wins by $7.9K in total portfolio value· pulled ahead in Year 7
10 years
AUOTY
AUOTY
● Live price
1.87%
Share price
$4.25
Annual div
$0.08
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$22.4K
Annual income
$211.45
Full AUOTY calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — AUOTY vs JNJ

📍 JNJ pulled ahead of the other in Year 7

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAUOTYJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AUOTY + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AUOTY pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AUOTY
Annual income on $10K today (after 15% tax)
$159.22/yr
After 10yr DRIP, annual income (after tax)
$179.73/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, JNJ beats the other by $3,806.26/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AUOTY + JNJ for your $10,000?

AUOTY: 50%JNJ: 50%
100% JNJ50/50100% AUOTY
Portfolio after 10yr
$26.3K
Annual income
$2,450.42/yr
Blended yield
9.30%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

AUOTY
Analyst Ratings
5
Buy
7
Hold
2
Sell
Consensus: Hold
Altman Z
1.1
Piotroski
8/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AUOTY buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAUOTYJNJ
Forward yield1.87%2.13%
Annual dividend / share$0.08$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$22.4K$30.3K
Annual income after 10y$211.45$4,689.40
Total dividends collected$2.0K$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldBuy

Year-by-year: AUOTY vs JNJ ($10,000, DRIP)

YearAUOTY PortfolioAUOTY Income/yrJNJ PortfolioJNJ Income/yrGap
1$10,887$187.31$10,592$272.30+$295.00AUOTY
2$11,840$190.59$11,289$357.73+$551.00AUOTY
3$12,863$193.71$12,123$472.89+$740.00AUOTY
4$13,960$196.67$13,141$629.86+$819.00AUOTY
5$15,136$199.48$14,408$846.81+$728.00AUOTY
6$16,398$202.15$16,021$1,151.60+$377.00AUOTY
7← crossover$17,750$204.67$18,122$1,588.22$372.00JNJ
8$19,200$207.06$20,930$2,228.20$1.7KJNJ
9$20,753$209.31$24,792$3,191.91$4.0KJNJ
10$22,418$211.45$30,274$4,689.40$7.9KJNJ

AUOTY vs JNJ: Complete Analysis 2026

AUOTYStock

AUO Corporation researches, develops, produces, and sells thin film transistor liquid crystal displays (TFT-LCDs) and other flat panel displays. It operates through two segments, Display and Energy. The company also designs, manufactures, and sells ingots, solar wafers, and solar modules, as well as provides technical engineering and maintenance services for solar system projects. In addition, it sells and leases content management system and related hardware; plans, designs, and develops construction project for environmental protection and related project management; and designs, manufactures, and sells TFT-LCD modules, TV sets and related parts, backlight modules, automotive parts, and precision plastic parts. Further, the company engages in the design, manufacture, and sale of InGaN epi wafers and chips, and light emitting diode packages and modules; development, manufacturing, and sale of medical equipment; services related to educational activities and site rental; research and development, and IP related business; solar power generation; and sale and sales support of TFTLCD panels. Additionally, it develops and sells software and hardware for health care industry; provides software and hardware integration system and equipment relating to intelligent manufacturing, as well as related consulting services; and investment services. The company operates in the People's Republic of China, Taiwan, Japan, Singapore, and internationally. The company was formerly known as AU Optronics Corp. and changed its name to AUO Corporation in June 2022. AUO Corporation was founded in 1996 and is headquartered in Hsinchu City, Taiwan.

Full AUOTY Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this AUOTY vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AUOTY vs SCHDAUOTY vs JEPIAUOTY vs OAUOTY vs KOAUOTY vs MAINAUOTY vs ABBVAUOTY vs MRKAUOTY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.